Онкогенетика и рак молочной железы

Vladimir P. Kharchenko, Кешелава Виктор Владимирович, Г. О. Шайхаев et al. · Вестник Российского университета дружбы народов. Серия: Медицина · 2006

Transforming growth factor beta TGF-p and it's receptor TGFBRl are growth inhibitors for certain cell types. TGF-P (T29C polymorphisms) and TGFBRl (TGFBRl *6A polymorphisms) carriers were twice higher among patients without a mutation in breast cancer genes. There were 150 patients with breast cancer genotyped for TGF-P (T29C polymorphisms) and it's receptor TGFBRl (TGFBRl *6A polymorphisms); mutations of genes BRCA 1 и BRCA2. There were revealed hereditary and sporadic cancer groups. 2 patients are under tamoxifen treatment according NSABP (National Surgical Adjuvant Breast Project Chemoprevention Trail) program. 4 patients have been made prophylactic bilateral subcutaneous mastectomy with alloplasty.

Cited by 0 works.

Authors